Life Sciences

  • May 11, 2026

    Plaintiffs' Attys Sanctioned In Tylenol MDL, Sparking Appeal

    A New York federal court sanctioned a plaintiffs' firm and its co-founder in federal multidistrict litigation by families alleging that prenatal exposure to acetaminophen can cause autism, saying they improperly shared confidential information from the case in related state court actions.

  • May 08, 2026

    Ex-FDA Chief Says J&J Atty 'Spinning' Asbestos Definition

    A former U.S. Food and Drug Administration commissioner told an attorney for Johnson & Johnson she was "spinning" the definition of asbestos in an attempt to confuse a jury in a bellwether trial over claims the company's talc products caused three women's deaths from ovarian cancer.

  • May 08, 2026

    FTC's Gender-Care Probe Likely Retaliatory, Judge Says

    The Endocrine Society has convinced a D.C. federal judge that the Federal Trade Commission's motivation for targeting it with a subpoena was likely retaliation for the guidelines the nonprofit produced regarding gender-affirming care.

  • May 08, 2026

    10x, Curio Settle Genomics Patent Suit Before Trial

    10x Genomics on Friday said it has agreed to end its suit accusing Curio Bioscience of infringing a series of Prognosys Biosciences genomics technology patents that 10x Genomics is licensed to use.

  • May 08, 2026

    Sports Tech Co. Says Judge Made Own Patent Eligibility Case

    Finnish sports tech company Polar Electro has asked the U.S. Supreme Court to revive its infringement case against a rival over a heart monitoring patent, saying a district judge made up his own case for patent eligibility when he ruled the patent was invalid.

  • May 08, 2026

    10x, Harvard Sue Sequencing Co. Over Biology Patents

    10x Genomics Inc. and Harvard have sued Element Biosciences Inc. in Delaware federal court, accusing the San Diego sequencing company of infringing four Harvard-owned patents through Element's AVITI24 platform and related Teton chemistry.

  • May 08, 2026

    Ex-Wachtell Lipton Atty Tied To Stolen BigLaw Info Trades

    A former Wachtell Lipton Rosen & Katz attorney who later worked for investment bank LionTree LLC is an unindicted co-conspirator in a sweeping alleged insider trading scheme that involved stolen information from several prominent law firms, according to a review of publicly available information.

  • May 08, 2026

    Covington, Cooley Lead Drugmaker Odyssey's $279M IPO

    Venture-backed biotechnology firm Odyssey Therapeutics began trading publicly Friday after raising $279 million in its initial public offering, making it the latest biotech to hit the public markets over the last few weeks.

  • May 08, 2026

    Squires Says Yes To 7 Patent Petitions, No To A Dozen More

    U.S. Patent and Trademark Office Director John Squires granted seven petitions for patent review under the America Invents Act and denied 12 other petitions, including a host of challenges by Cisco Systems and Samsung Electronics.

  • May 08, 2026

    Don't Miss It: Paul Hastings, V&E Steer Latest Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple weeks, and it's difficult to keep up with all the deals.

  • May 08, 2026

    Catalent Agrees To Pay $78M To Settle Securities Suit

    Catalent Inc. agreed on Thursday to pay $78 million to settle a securities class action from a group of investors who alleged the vaccine manufacturer engaged in accounting and channel stuffing schemes and cut corners on safety to pad its revenues.

  • May 08, 2026

    Walgreens Loses Atty Sanctions Bid In Georgia Bias Suit

    The attorney for a former pharmacist suing Walgreens for discrimination has escaped a sanctions bid after a Georgia federal judge found the chain gave the lawyer too little time to respond to a motion to dismiss claims.

  • May 08, 2026

    Cardiac Device Co. Says Ex-Manager Took Secrets To Rival

    Vital Connect Inc., a company that sells wearable cardiac monitoring devices, told a North Carolina federal court that a former senior key accounts manager pilfered its confidential information only to decamp to a competitor and begin soliciting its clients.

  • May 08, 2026

    Squires Says Fitness Tracker Patent Date Key To PGR Ruling

    Wearable technology company Whoop Inc. has shown that an Omni Medsci Inc. patent can be challenged under the America Invents Act because its effective filing was after a cutoff date in the law, U.S. Patent and Trademark Office Director John Squires has found.

  • May 07, 2026

    Fed. Circ. Judges Stuck On Drug Efficacy's Role In Patents

    A Federal Circuit panel struggled Thursday to pin down where the line is between patent enablement on cancer drug patents and U.S. Food and Drug Administration standards, as a Pfizer unit tried to revive its $107 million jury victory over AstraZeneca.

  • May 07, 2026

    J&J Feared FDA's 'Disturbing Proposal' To Test Talc, Jury Told

    A former U.S. Food and Drug Administration commissioner testifying Thursday in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused three women's deadly ovarian cancer described an internal document showing J&J feared the FDA's "disturbing proposal" to test the talc instead of relying on industry self-testing.

  • May 07, 2026

    La. Says Mailed Abortion Pills Harm State Budget, Sovereignty

    The state of Louisiana on Thursday defended its standing to challenge telehealth access to the abortion medication mifepristone, telling the U.S. Supreme Court that it has suffered financial and other injuries as mail-order pills flood the state.

  • May 07, 2026

    Judge, In 'Difficult Position,' OKs Rare Patent Defense

    A Massachusetts federal judge found himself in what he said was a "difficult position" in allowing an unusual defense to be advanced in a patent infringement case related to blood pumps in light of criticism of the defense from the Federal Circuit.

  • May 07, 2026

    $495M Win Upheld In Abbott Baby Formula Bellwether Trial

    A Missouri appellate panel on Tuesday upheld a trial win of $95 million in compensatory damages and $400 million in punitive damages over bellwether claims that Abbott Laboratories' baby formula caused a premature baby to suffer a fully disabling condition.

  • May 07, 2026

    Bayer Sued Over Healthy Sperm Claim On 'One A Day' Pill

    Bayer AG has been hit with a proposed class action in New York federal court alleging that claims on its Men's One A Day Pre-Conception Health Multivitamin supplements misleadingly convey that they could improve chances of conception and support sperm health.

  • May 07, 2026

    Bayer Loses Bid To Undo Class In 'One A Day' Label Suit

    A New York federal judge on Wednesday declined to decertify a class action alleging that Bayer's "One A Day" gummy vitamins deceive consumers about serving sizes, allowing the case to continue since there's evidence that a significant number of consumers could be confused.

  • May 07, 2026

    Liberty Left Client Info Vulnerable To Hackers, Suit Alleges

    Liberty Mutual Insurance Co. faces a proposed consumer class action alleging it failed to effectively safeguard private information for current and former clients after hackers claimed they stole information and sought a ransom payment.

  • May 07, 2026

    Judge Knocks Out Pfizer Partner's Vax Case Against GSK

    A Delaware federal judge on Thursday threw out a suit seeking a finding that a drug developer that partnered with Pfizer and BioNTech on their COVID-19 vaccine didn't infringe drugmaker GlaxoSmithKline's patents.

  • May 07, 2026

    Pharma Cos. Hit With $2M Judgment Over CBD Investor Fraud

    A California federal judge has issued final judgments against a pharmaceutical company, its CEO and an affiliate on claims from the U.S. Securities and Exchange Commission that they defrauded investors of $6.6 million, hitting them with more than $2 million in damages and civil penalties.

  • May 07, 2026

    AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit

    Female pharmaceutical sales representatives in an AstraZeneca equal pay suit have urged an Illinois federal court to reject the company's bid to dismiss two dozen opt-in plaintiffs for refusing discovery, saying the women feared retaliation and career consequences.

Expert Analysis

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.